Skip to main content
Premium Trial:

Request an Annual Quote

Illumina to Perform Mouse Genotyping Study for Wellcome Trust

NEW YORK, Aug 12 (GenomeWeb) - Illumina has signed an agreement to perform a large-scale mouse genotyping study for the Wellcome Trust Centre for Human Genetics at Oxford University.

 

Under the fast-track services pact, Illumina will generate over 25 million mouse genotypes for Wellcome Trust researchers, who will use SNP variants to search for quantitative trait loci. Since specific genes and gene order are highly conserved between mouse and human species, the partners believe that the information yielded from this study should promote a more rapid identification of disease genes and genetic functions in humans.

 

The Wellcome Trust will provide Illumina with SNP loci and samples from inbred mouse crosses. San Diego-based Illumina will develop the assays for high-multiplex genotyping using its GoldenGate protocol.

 

The alliance follows a pilot study the firm completed in 2003 for Oxford and the Genomics Institute of the Novartis Research Foundation and is expected to result in Illumina marketing a standard mouse panel for generating genotypes with predictive value for behavioral disorders.

 

The Wellcome Trust plans to publish the genotyping results and make the information available freely to other researchers and the general public.

The Scan

Dropped Charges

The US Justice Department has dropped visa fraud charges against five Chinese researchers, according to the Wall Street Journal.

More Kids

The Associated Press says Moderna is expanding its SARS-CoV-2 vaccine study to included additional children and may include even younger children.

PNAS Papers on Rat Clues to Human Migration, Thyroid Cancer, PolyG-DS

In PNAS this week: ancient rat genome analysis gives hints to human migrations, WDR77 gene mutations in thyroid cancer, and more.

Purnell Choppin Dies

Purnell Choppin, a virologist who led the Howard Hughes Medical Institute, has died at 91, according to the Washington Post.